The two biotech stocks highlighted in today’s article both made their public market debuts in 2018 – and both have performed very well for investors who have held them from the beginning. More importantly, for investors who missed out on this outperformance, the author believes there’s good reason to expect further outperformance from both stocks going forward, making them both potential buys right now. For more, CLICK HERE.